janumet 50 mg / 1000 mg
orifarm as - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg
janumet 50 mg / 850 mg
orifarm as - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg
janumet 50 mg / 1000 mg
paranova as (1) - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg
janumet 50 mg / 1000 mg
2care4 aps - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg
janumet 50 mg / 850 mg
2care4 aps - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg
januvia 25 mg
orifarm as - sitagliptinfosfatmonohydrat - tablett, filmdrasjert - 25 mg
januvia 100 mg
orifarm as - sitagliptinfosfatmonohydrat - tablett, filmdrasjert - 100 mg
xelevia 25 mg
orifarm as - sitagliptinfosfatmonohydrat - tablett, filmdrasjert - 25 mg
januvia 50 mg
orifarm as - sitagliptinfosfatmonohydrat - tablett, filmdrasjert - 50 mg
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karsinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.